Stifel raised the firm’s price target on Stryker (SYK) to $440 from $400 and keeps a Buy rating on the shares following “an excellent finish to the 2024 year” with better-than-expected Q4 performance across multiple key metrics. Underpinning the positive quarter, management emphasized several encouraging hospital environment trends that “appear to augur well for the 2025 outlook,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
Questions or Comments about the article? Write to editor@tipranks.com